Improving the outcome of patients with castration-resistant prostate cancer through rational drug development

British Journal of Cancer

Volumn 95, Issue 7, 2006, Pages 767-774

  Attard, G ^a   Sarker, D ^a   Reid, A ^a   Molife, R ^a   Parker, C ^a   De Bono, J S ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Castration resistance; Prostate cancer; Targeted therapies

Indexed keywords

17 ALLYLAMINO 17 DEMETHOXYGELDANAMYCIN; 17 DEMETHYLAMINOETHYLAMINO 17 DEMETHOXYGELDANAMYCIN; 4 (4 FLUORO 2 METHYL 5 INDOLYLOXY) 6 METHOXY 7 [3 (1 PYRROLIDINYL)PROPOXY]QUINAZOLINE; ANTIANDROGEN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BICALUTAMIDE; CP 751 851; DIETHYLSTILBESTROL; DN 101; DOCETAXEL; E 7389; ESTROGEN; EVEROLIMUS; FLUTAMIDE; FR 901228; GEFITINIB; GLUCOCORTICOID; GONADORELIN AGONIST; GOSERELIN; IXABEPILONE; LEUPRORELIN; OBLIMERSEN; PERTUZUMAB; PI 103; SATRAPLATIN; SEOCALCITOL; SORAFENIB; TAXANE DERIVATIVE; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; YM 155; ZSTK 474;

CANCER CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RESISTANCE; CANCER STEM CELL; CANCER SURGERY; CANCER SURVIVAL; CARCINOGENESIS; CASTRATION; CAUSE OF DEATH; CHROMOSOME TRANSLOCATION; CLINICAL RESEARCH; CLINICAL TRIAL; DOWNSTREAM PROCESSING; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG TARGETING; GENE AMPLIFICATION; GENE MUTATION; HORMONE INHIBITION; HUMAN; INTRACELLULAR SPACE; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN FAMILY; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY; SHORT SURVEY; SIGNAL TRANSDUCTION; STEROIDOGENESIS; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; CASTRATION; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RECEPTORS, ANDROGEN;

EID: 33749345244     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6603223     Document Type: Short Survey

References (39)

1. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W (2004) High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 10: 6572-6578
2. Banerji U, O'Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y, Simmons L, Maloney A, Raynaud F, Campbell M, Walton M, Lakhani S, Kaye S, Workman P, Judson I (2005) Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 23: 4152-4161
3. Beer TM, Myrthue A, Eilers KM (2005) Rationale for the development and current status of calcitriol in androgen-independent prostate cancer. World J Urol 23: 28-32
4. Berthold DR, Sternberg CN, Tannock IF (2005) Management of advanced prostate cancer after first-line chemotherapy. J Clin Oncol 23: 8247-8252
5. Birtle AJ, Newby JC, Harland SJ (2004) Epirubicin carboplatin and 5-fluorouracil (ECarboF) chemotherapy in metastatic hormone refractory prostate cancer. Br J Cancer 91: 1472-1476
6. Burtrum D, Zhu Z, Lu D, Anderson DM, Prewett M, Pereira DS, Bassi R, Abdullah R, Hooper AT, Koo H, Jimenez X, Johnson D, Apblett R, Kussie P, Bohlen P, Witte L, Hicklin DJ, Ludwig DL (2003) A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signalling and inhibits human tumor growth in vivo. Cancer Res 63: 8912-8921
7. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, Berry S, Ernst DS, Douglas L, Brundage M, Fisher B, McKenna A, Seymour L (2005) Randomized phase II study of two doses of gefitinib in hormonerefractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 23: 455-460
8. Carducci MA, Padley RJ, Bruel J, Vozelgang NJ, Zonnenberg BA, Daliani DD, Schulman CC, Nabulsi AA, Humerickhouse RA, Winberg MA, Schmitt JL, Nelson JB (2003) Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomised, phase II, placebo-controlled trial. J Clin Oncol 21: 679-689
9. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, Rosenfeld MG, Sawyers CL (2004) Molecular determinants of resistance to antiandrogen therapy. Nat Med 10: 33-39
10. Chen L, Meng S, Wang H, Bali P, Bai W, Li B, Atadja P, Bhalla KN, Wu J (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther 4: 1311-1319
11. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ (2005) Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946-10951
12. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, Hayes DF (2004) Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 351: 781-791
13. De Bono JS, Bellmunt J, Droz JP, Miller G, Zugmaier G, Sternberg C, Gimenez V, Parker C, Mason M, Graham J (2005) An open label, phase II, multicenter, study to evaluate the efficacy and safety of pertuzumab (P) in chemotherapy naïve patients (pts) with Hormone Refractory Prostate Cancer (HRPC). J Clin Oncol ASCO Ann Meet Proc 23(16S): 4609
14. Di Lorenzo G, Tortora G, D'Armiento FP, De Rosa G, Staibano S, Autorino R, D'Armiento M, De Laurentiis M, De Placido S, Catalano G, Bianco AR, Ciardiello F (2002) Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer. Clin Cancer Res 8: 3438-3444
15. Edwards J, Bartlett JM (2005) The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int 95: 1320-1326
16. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK (2005) Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 23: 1439-1446
17. Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB (2005) Exploiting the PI3K/AKT pathway for cancer drug discovery. Nat Rev Drug Discov 4: 988-1004
18. Kuznetsov G, Towle MJ, Cheng H, Kawamura T, TenDyke K, Liu D, Kishi Y, Yu MJ, Littlefield BA (2004) Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by the halichondrin B macrocyclic ketone analog E7389. Cancer Res 64: 5760-5766
19. Li J, Wang E, Rinaldo F, Datta K (2005) Upregulation of VEGF-C by androgen depletion: the involvement of IGF-IR-FOXO pathway. Oncogene 24: 5510-5520
20. Majumder PK, Febbo PG, Bikoff R, Berger R, Xue Q, McMahon LM, Manola J, Brugarolas J, McDonnell TJ, Golub TR, Loda M, Lane HA, Sellers WR (2004) mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 10: 594-601
21. Mellinghoff IK, Vivanco I, Kwon A, Tran C, Wongvipat J, Sawyers CL (2004) HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability. Cancer Cell 6: 517-527
22. Montgomery RB, Bonham M, Nelson PS, Grim J, Makary E, Vessella R, Stahl WL (2005) Estrogen effects on tubulin expression and taxane mediated cytotoxicity in prostate cancer cells. Prostate 65: 141-150
23. Nilsson S, Larsen RH, Fossa SD, Balteskard L, Borch KW, Westlin JE, Salberg G, Bruland OS (2005) First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res 11: 4451-4459
24. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M (2004) Hormonal impact of the 17alpha-hydroxylase/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90: 2317-2325
25. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D, Lane H, Hofmann F, Hicklin DJ, Ludwig DL, Baselga J, Rosen N (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508
26. Pollak MN, Schernhammer ES, Hankinson SE (2004) Insulin-like growth factors and neoplasia. Nat Rev Cancer 4: 505-518
27. Rozhansky F, Chen MH, Cox MC, Dahut W, Figg WD, D'Amico AV (2006) Prostate-specific antigen velocity and survival for patients with hormone-refractory metastatic prostate carcinoma. Cancer 106: 63- 67
28. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96: 879-882
29. Seligson D, Horvarth S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435: 1262-1266
30. She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N (2005) The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287-297
31. Small EJ, Halabi S, Dawson NA, Stadler WM, Rini BI, Picus J, Gable P, Torti FM, Kaplan E, Vogelzang NJ (2004) Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 22: 1025-1033
32. Solit DB, Scher H, Rosen N (2003) Hsp90 as a therapeutic target in prostate cancer. Semin Oncol 30: 709-716
33. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512
34. Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL (2005) Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res 11: 4653-4657
35. Tolcher AW, Chi K, Kuhn J, Gleave M, Patnaik A, Takimoto C, Schwartz G, Thompson I, Berg K, D'Aloisio S, Murray N, Frankel SR, Izbicka E, Rowinsky E (2005) A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11: 3854- 3861
36. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM (2005) Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 310: 644-648
37. Workman P (2003) How much gets there and what does it do? The need for better pharmacokinetic and pharmacodynamic endpoints in contemporary drug discovery and development. Curr Pharm Des 9: 891-902
38. Zhang M, Latham DE, Delaney MA, Chakravarti A (2005) Survivin mediates resistance to antiandrogen therapy in prostate cancer. Oncogene 24: 2474-2482
39. Ziada A, Barqawi A, Glode LM, Varella-Garcia M, Crighton F, Majeski S, Rosenblum M, Kane M, Chen L, Crawford ED (2004) The use of trastuzumab in the treatment of hormone refractory prostate cancer; phase II trial. Prostate 60: 332-337